Imunon, Inc. (0HUZ.L)
USD 0.83
(-0.97%)
USD 0.83
(-0.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.78 Million USD | 14.09% |
| 2022 | -24.18 Million USD | -19.14% |
| 2021 | -20.3 Million USD | -14.42% |
| 2020 | -17.74 Million USD | 10.58% |
| 2019 | -19.84 Million USD | 4.17% |
| 2018 | -21.23 Million USD | -15.59% |
| 2017 | -17.91 Million USD | 8.69% |
| 2016 | -19.62 Million USD | 3.88% |
| 2015 | -20.41 Million USD | 11.06% |
| 2014 | -23.79 Million USD | -52.36% |
| 2013 | -15.06 Million USD | 31.07% |
| 2012 | -21.85 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.94 Million USD | -4.08% |
| 2024 Q1 | -4.83 Million USD | 21.18% |
| 2023 Q3 | -3.7 Million USD | 29.89% |
| 2023 FY | - USD | 16.04% |
| 2023 Q4 | -5.82 Million USD | -57.24% |
| 2023 Q1 | -5.49 Million USD | 18.14% |
| 2023 Q2 | -5.28 Million USD | 3.75% |
| 2022 Q3 | -6 Million USD | -3.32% |
| 2022 FY | - USD | -19.14% |
| 2022 Q4 | -6.7 Million USD | -11.76% |
| 2022 Q2 | -5.81 Million USD | -2.51% |
| 2022 Q1 | -5.66 Million USD | -6.33% |
| 2021 Q1 | -5.19 Million USD | -12.29% |
| 2021 FY | - USD | -14.42% |
| 2021 Q2 | -4.87 Million USD | 6.06% |
| 2021 Q4 | -5.33 Million USD | -8.73% |
| 2021 Q3 | -4.9 Million USD | -0.5% |
| 2020 Q3 | -3.96 Million USD | 13.33% |
| 2020 Q4 | -4.62 Million USD | -16.59% |
| 2020 FY | - USD | 10.58% |
| 2020 Q2 | -4.57 Million USD | 0.03% |
| 2020 Q1 | -4.57 Million USD | -0.32% |
| 2019 Q3 | -5.21 Million USD | 3.41% |
| 2019 Q1 | -4.67 Million USD | -21.19% |
| 2019 FY | - USD | 4.17% |
| 2019 Q4 | -4.56 Million USD | 12.45% |
| 2019 Q2 | -5.39 Million USD | -15.52% |
| 2018 Q2 | -7.92 Million USD | -88.94% |
| 2018 Q1 | -4.19 Million USD | 9.61% |
| 2018 FY | - USD | -15.59% |
| 2018 Q4 | -3.85 Million USD | 2.03% |
| 2018 Q3 | -3.93 Million USD | 50.34% |
| 2017 Q4 | -4.63 Million USD | -9.75% |
| 2017 FY | - USD | 8.69% |
| 2017 Q3 | -4.22 Million USD | 3.92% |
| 2017 Q2 | -4.4 Million USD | 5.33% |
| 2017 Q1 | -4.64 Million USD | -3.96% |
| 2016 Q4 | -4.47 Million USD | 18.33% |
| 2016 Q2 | -4.61 Million USD | 8.66% |
| 2016 FY | - USD | 3.88% |
| 2016 Q1 | -5.05 Million USD | -4.39% |
| 2016 Q3 | -5.47 Million USD | -18.53% |
| 2015 Q4 | -4.84 Million USD | -17.23% |
| 2015 Q3 | -4.13 Million USD | 19.52% |
| 2015 Q2 | -5.13 Million USD | 18.54% |
| 2015 Q1 | -6.3 Million USD | 10.19% |
| 2015 FY | - USD | 11.06% |
| 2014 Q3 | -5.76 Million USD | -9.57% |
| 2014 Q4 | -7.01 Million USD | -21.82% |
| 2014 FY | - USD | -52.36% |
| 2014 Q2 | -5.25 Million USD | -2.81% |
| 2014 Q1 | -5.11 Million USD | -73.59% |
| 2013 Q1 | -4.69 Million USD | 7.77% |
| 2013 Q3 | -3.45 Million USD | 8.34% |
| 2013 Q4 | -2.94 Million USD | 14.77% |
| 2013 FY | - USD | 31.07% |
| 2013 Q2 | -3.77 Million USD | 19.59% |
| 2012 Q4 | -5.08 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 87.259% |
| Dynavax Technologies Corporation | 9.66 Million USD | 315.004% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 121.15% |
| Perrigo Company plc | 646.2 Million USD | 103.216% |
| Illumina, Inc. | -608 Million USD | 96.582% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.192% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 95.372% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.816% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 100.638% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 79.977% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.447% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 44.258% |
| Waters Corporation | 1.02 Billion USD | 102.033% |
| Biogen Inc. | 2.37 Billion USD | 100.874% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 76.229% |
| Evolus, Inc. | -41.81 Million USD | 50.294% |
| Adicet Bio, Inc. | -136.53 Million USD | 84.779% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 82.336% |
| bluebird bio, Inc. | -167.16 Million USD | 87.568% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 86.155% |
| FibroGen, Inc. | -261.4 Million USD | 92.05% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 101.239% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 53.232% |
| Homology Medicines, Inc. | -47.75 Million USD | 56.482% |
| Geron Corporation | -174.78 Million USD | 88.11% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 90.89% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 77.43% |
| Myriad Genetics, Inc. | -67.8 Million USD | 69.348% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 79.388% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 95.895% |
| Zoetis Inc. | 3.68 Billion USD | 100.564% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 58.906% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 101.785% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 106.698% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.451% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 42.403% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 90.965% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 92.187% |
| Verastem, Inc. | -83.16 Million USD | 75.011% |
| Nektar Therapeutics | -243.1 Million USD | 91.451% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 90.763% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 76.38% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 95.268% |
| OPKO Health, Inc. | -65.51 Million USD | 68.279% |
| Exelixis, Inc. | 196.6 Million USD | 110.571% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 104.995% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 119.185% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 62.726% |
| uniQure N.V. | -253.1 Million USD | 91.789% |
| Blueprint Medicines Corporation | -474.61 Million USD | 95.621% |
| Insmed Incorporated | -654.73 Million USD | 96.826% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 104.598% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 93.984% |
| TG Therapeutics, Inc. | 26.1 Million USD | 179.626% |
| Incyte Corporation | 919.42 Million USD | 102.26% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 95.887% |